You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

IL-1 receptor antagonist

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Rectal Cancer Trial in Frankfurt (drug, radiation, procedure)

Recruiting
  • Rectal Cancer
  • Kineret 100 MG in 0.67 ML Prefilled Syringe
  • +3 more
  • Frankfurt, Germany
    University Hospital Goethe University Frankfurt
Aug 23, 2022

Diabetes Type 2 in Obese, Inflammation, Metabolic Disease Trial in Basel (Anakinra Prefilled Syringe)

Recruiting
  • Diabetes Mellitus Type 2 in Obese
  • +3 more
  • Anakinra Prefilled Syringe
  • Basel, Basel BS, Switzerland
    University Hospital Basel
Sep 7, 2021

B Cell ALL, B-Cell Lymphoma, B-cell Non Hodgkin Lymphoma Trial in Hackensack, New York (Anakinra)

Recruiting
  • B Cell ALL
  • +2 more
  • Hackensack, New Jersey
  • +1 more
Aug 22, 2022

Clinical Phenotypes in Pericarditis: IL-1RA Antibodies and suPAR

Not yet recruiting
  • Pericarditis
  • IL1RA Antibody Assay
  • suPAR Testing
  • Homburg, Germany
  • +8 more
Jun 22, 2023

End-Stage Renal Disease Trial in United States (Anakinra, Placebo)

Completed
  • End-Stage Renal Disease
  • Washington, District of Columbia
  • +3 more
Jan 19, 2022

Intracerebral Haemorrhage Trial in Manchester (IL-1Ra Kineret®, IL-1Ra Placebo)

Completed
  • Intracerebral Haemorrhage
  • IL-1Ra Kineret®
  • IL-1Ra Placebo
  • Manchester, North West, United Kingdom
    Salford Royal NHS Foundation Trust
Oct 4, 2021

Polycystic Ovary Syndrome Trial in Basel (IL-1 receptor antagonist Anakinra)

Completed
  • Polycystic Ovary Syndrome
  • IL-1 receptor antagonist Anakinra
  • Basel, Switzerland
    University Hospital Basel Endocrinology, Diabetes and Metabolism
Jan 26, 2021

GDM Patients and Serum Amyloid A and Interleukin-1 Receptor

Completed
  • Gestational Diabetes
  • Serum amyloid A values
  • Interleukin-1 (IL-1) receptor antagonist values (A-SAA and IL-1Ra)
  • Istanbul, Turkey
    Kanuni Sultan Süleyman Training and Research Hospital
May 21, 2020

Subarachnoid Hemorrhage Trial in United Kingdom (IL-1Ra, IL-1Ra Placebo)

Recruiting
  • Subarachnoid Hemorrhage
  • Plymouth, Devon, United Kingdom
  • +11 more
May 16, 2022

Adamantinomatous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma Trial in Worldwide (Tocilizumab)

Recruiting
  • Adamantinomatous Craniopharyngioma
  • Recurrent Adamantinomatous Craniopharyngioma
  • Aurora, Colorado
  • +17 more
Jan 8, 2023

Advanced Malignant Tumor, Metastatic Malignant Tumor, Recurrent Malignant Tumor Trial in Houston (Anakinra, Denosumab,

Completed
  • Advanced Malignant Neoplasm
  • +3 more
  • Anakinra
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 24, 2021

COVID-19 Pnemonia Trial in Spain (Anakinra 149 MG/ML Prefilled Syringe [Kineret])

Completed
  • COVID-19 Pnemonia
  • Anakinra 149 MG/ML Prefilled Syringe [Kineret]
  • Zaragoza, Aragón, Spain
  • +11 more
May 27, 2021

Myeloma Trial in Houston (Fludarabine phosphate, Cyclophosphamide, NY-ESO-1 TCR/IL-15 NK)

Not yet recruiting
  • Myeloma
  • Fludarabine phosphate
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 27, 2023

Malignant Pleural Effusion, Malignant Ascites Trial in Pittsburgh (Tocilizumab)

Not yet recruiting
  • Malignant Pleural Effusion
  • Malignant Ascites
  • Pittsburgh, Pennsylvania
    Allegheny Health Network Cancer Institute
Aug 30, 2023

Netosis During COVID-19, Under Treatment With

Active, not recruiting
  • Covid19
    • Paris, France
    • +1 more
    Mar 30, 2022

    Epidermolysis Bullosa Trial in Redwood City (Serlopitant Tablet, Placebo Oral Tablet)

    Completed
    Has Results
    • Epidermolysis Bullosa
    • Serlopitant Tablet
    • Placebo Oral Tablet
    • Redwood City, California
      Stanford University
    Nov 30, 2022

    Safety Issues, Pain, Pancreas Fibrosis Trial in Washington (Proglumide, Placebo)

    Recruiting
    • Safety Issues
    • +2 more
    • Washington, District of Columbia
      Georgetown University
    Dec 1, 2022

    HIV, Neurologic Disorders Trial in Baltimore, Bethesda (Anakinra)

    Terminated
    • HIV Infections
    • Neurologic Disorders
    • Baltimore, Maryland
    • +1 more
    Nov 27, 2019

    IL-1ß and Its Receptor Antagonists in Treatment of Severe

    Withdrawn
    • Critical Illness
    • Sepsis, Severe
      • (no location specified)
      Jun 13, 2022

      Prostatic Tumors Trial in Beijing, NanJing, ShangHai (Apalutamide)

      Active, not recruiting
      • Prostatic Neoplasms
      • Beijing, China
      • +3 more
      Jan 17, 2023

      Synovial Sarcoma Trial in Houston (Fludarabine phosphate, NY-ESO-1 TCR/IL-15 NK, Cyclophosphamide)

      Not yet recruiting
      • Synovial Sarcoma
      • Fludarabine phosphate
      • +2 more
      • Houston, Texas
        MD Anderson Cancer Center
      Oct 9, 2023

      Depressive Disorder, Major, Anxiety Disorder Trial (Nociceptin Receptor Antagonist, Aversive stimuli)

      Not yet recruiting
      • Depressive Disorder, Major
      • Anxiety Disorder
      • Nociceptin Receptor Antagonist
      • Aversive stimuli
      • (no location specified)
      Nov 3, 2022

      Exercise, Histamine Trial in Ghent (Placebo: Placebo + exercise training., H1 blockade: H1 receptor antagonist + exercise

      Active, not recruiting
      • Exercise
      • Histamine
      • Placebo: Placebo + exercise training.
      • +2 more
      • Ghent, Oost-Vlaanderen, Belgium
        Department of movement and sports sciences, Ghent University, Be
      Nov 8, 2022

      Renal Cell Carcinoma Trial in Houston (Ipilimumab, Nivolumab, Ciforadenant)

      Not yet recruiting
      • Renal Cell Carcinoma
      • Houston, Texas
        M D Anderson Cancer Center
      Aug 11, 2022

      Lung Cancer Trial in Houston (Cemiplimab, Kevzara (Sarilumab))

      Not yet recruiting
      • Lung Cancer
      • Houston, Texas
        M D Anderson Cancer Center
      Jan 19, 2023